Literature DB >> 19487260

Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis.

Yoland Schoindre1, Christophe Meune, Anh Tuan Dinh-Xuan, Jérôme Avouac, André Kahan, Yannick Allanore.   

Abstract

OBJECTIVE: The 6-minute walk test (6MWT) is an important prognostic tool in various cardiovascular diseases and has been considered as a surrogate endpoint. However, conflicting results have been reported in systemic sclerosis (SSc). Our objective was to evaluate the relationships of the 6-min walking distance (6MWD) and organ damage in SSc.
METHODS: Eighty-seven consecutive patients with SSc were included and prospectively investigated; they underwent 6MWT in addition to conventional assessment of possible lung, heart, kidney, skin, and muscle involvement, and disease activity scoring, severity, and quality of life determination.
RESULTS: Twenty-six patients (30%) had an abnormal 6MWT and the mean 6MWD was 461.8 +/- 103.0 m. When considering 6MWT as a binary variable - normal or abnormal - C-reactive protein (CRP) was the only independent variable associated with abnormal 6MWT. Considered as a continuous variable, the 6MWD was associated with measures of lung involvement and inflammation, with the activity and severity of disease, and also with quality of life; nevertheless, calcinosis was the only independent factor associated in multivariate analyses with a trend for an association for CRP.
CONCLUSION: The 6MWD relates to broad factors in SSc and these results raise doubts about the specificity of the 6MWD in this systemic disease, and its relevance to monitoring therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19487260     DOI: 10.3899/jrheum.081221

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Authors:  Beth Wallace; Suzanne Kafaja; Daniel E Furst; Veronica J Berrocal; Peter A Merkel; James R Seibold; Maureen D Mayes; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2015-02-09       Impact factor: 7.580

2.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

3.  Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.

Authors:  Matthew R Lammi; Lesley A Saketkoo; Jessica K Gordon; Paula Lauto; Karen Fagan; Virginia D Steen
Journal:  Respirology       Date:  2017-05-12       Impact factor: 6.424

4.  Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.

Authors:  Rennie L Rhee; Nicole B Gabler; Sapna Sangani; Amy Praestgaard; Peter A Merkel; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

Review 5.  Points to consider when doing a trial primarily involving the heart.

Authors:  Yannick Allanore; Oliver Distler; Ulrich A Walker; Dinesh Khanna; Daniel E Furst; Christophe Meune
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 6.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

7.  Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Authors:  Rennie L Rhee; Nicole B Gabler; Amy Praestgaard; Peter A Merkel; Steven M Kawut
Journal:  Arthritis Rheumatol       Date:  2015-09       Impact factor: 10.995

8.  Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.

Authors:  Omar A Minai; Quyen Nguyen; Srinivas Mummadi; Esteban Walker; Kevin McCarthy; Raed A Dweik
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 9.  Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Authors:  Marc Humbert; Manjit Singh; Daniel E Furst; Dinesh Khanna; James R Seibold
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 10.  Systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Neal F Chaisson; Paul M Hassoun
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.